Randomised phase II study to optimise melphalan, prednisolone, and bortezomib in untreated multiple myeloma (JCOG1105)
Open Access
- 1 February 2021
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 192 (3), 531-541
- https://doi.org/10.1111/bjh.16878
Abstract
We conducted a randomised phase II study to determine the optimal dose and schedule of melphalan, prednisone, and bortezomib (MPB) (jRCTs031180097). Transplant-ineligible untreated multiple myeloma patients were randomised to Arm A (twice weekly bortezomib in one six-week cycle followed by eight five-week cycles of four times once weekly bortezomib with melphalan and prednisolone on days 1-4) or Arm B (nine four-week cycles of three times once weekly bortezomib with melphalan and prednisolone on days 1-4). The primary end-point was complete response (CR) rate. Of 91 patients randomised to two arms, 88 were eligible. The median cumulative bortezomib doses were 45 center dot 8 and 35 center dot 1 mg/m(2), CR rate was 18 center dot 6% [95% confidence interval (CI) 8 center dot 4-33 center dot 4] and 6 center dot 7% (95% CI 1 center dot 4-18 center dot 3), and the median progression-free survival (PFS) was 2 center dot 5 and 1 center dot 4 years in Arms A and B [hazard ratio (HR) 1 center dot 93 (95% CI 1 center dot 09-3 center dot 42)], respectively. Frequent grade >= 3 haematologic toxicities in Arms A and B were neutropenia (64 center dot 4% vs. 28 center dot 3%) and thrombocytopenia (35 center dot 6% vs. 10 center dot 9%). Grade 2/3 peripheral neuropathy was observed in 24 center dot 4/2 center dot 2% in Arm A and 8 center dot 7/0% in Arm B. In conclusion, Arm A was the more promising regimen, suggesting that the twice weekly schedule of bortezomib in the first cycle and higher cumulative dose of both bortezomib and melphalan influences the efficacy of modified MPB.Funding Information
- Japan Agency for Medical Research and Development (JP16ck0106077, JP19ck0106348)
This publication has 28 references indexed in Scilit:
- Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple MyelomaThe New England Journal of Medicine, 2015
- Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapyHaematologica, 2014
- Global real-time quantitative reverse transcription-polymerase chain reaction detecting proto-oncogenes associated with 14q32 chromosomal translocation as a valuable marker for predicting survival in multiple myelomaLeukemia Research, 2013
- Phase I/II study of bortezomib‐melphalan‐prednisolone for previously untreated Japanese patients with multiple myelomaCancer Science, 2013
- Efficacy and safety of once-weekly bortezomib in multiple myeloma patientsBlood, 2010
- Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled TrialJournal of Clinical Oncology, 2010
- Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trialThe Lancet Oncology, 2010
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple MyelomaThe New England Journal of Medicine, 2008
- International uniform response criteria for multiple myelomaLeukemia, 2006
- Presalvage prostate‐specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapyCancer, 2006